NT 503

Drug Profile

NT 503

Alternative Names: Encapsulated VEGF inhibitor - Neurotech; NT-503; NT-503-2; NT-503-3; Wet AMD encapsulated cell therapy - Neurotech

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Neurotech USA
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Choroidal neovascularisation

Most Recent Events

  • 18 Oct 2016 Neurotech USA terminates phase II portion of a phase I/II trial in Choroidal neovascularisation (Recurrent, Treatment-experienced) in USA and Israel (Neurotech USA pipeline, July 2016)
  • 17 Apr 2016 Biomarkers information updated
  • 30 Mar 2015 Phase-II clinical trials in Choroidal neovascularisation (Recurrent, Treatment-experienced) in Israel (Intraocular) (NCT02228304)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top